Browsing by Author "Moura, Brenda"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
- Correction to: worsening heart failure: progress, pitfalls, and perspectives (Heart Failure Reviews, (2025), 10.1007/s10741-025-10497-z)Publication . Fonseca, Cândida; Baptista, Rui; Franco, Fátima; Moura, Brenda; Pimenta, Joana; Sarmento, Pedro Moraes; Cardoso, José Silva; Brito, DulceThe order of the authors' first and last names was reversed in the original publication. The correct author names are as follows: Incorrect Author List: Fonseca Cândida · Baptista Rui · Franco Fátima · Moura Brenda · Pimenta Joana · Pedro Moraes Sarmento · Silva Cardoso José · Brito Dulce Correct Author List: Cândida Fonseca · Rui Baptista · Fátima Franco · Brenda Moura · Joana Pimenta · Pedro Moraes Sarmento · José Silva Cardoso · Dulce Brito The original article has been corrected.
- A Portuguese expert panel position paper on the management of heart failure with preserved ejection fraction - part I: pathophysiology, diagnosis and treatmentPublication . Silva-Cardoso, José; Moreira, Emília; Melo, Rachel Tavares de; Moraes-Sarmento, Pedro; Cardim, Nuno; Oliveira, Mário; Gavina, Cristina; Moura, Brenda; Araújo, Inês; Santos, Paulo; Peres, Marisa; Fonseca, Cândida; Ferreira, João Pedro; Marques, Irene; Andrade, Aurora; Baptista, Rui; Brito, Dulce; Cernadas, Rui; Santos, Jonathan dos; Leite-Moreira, Adelino; Gonçalves, Lino; Ferreira, Jorge; Aguiar, Carlos; Fonseca, Manuela; Fontes-Carvalho, Ricardo; Franco, Fátima; Lourenço, Carolina; Martins, Elisabete; Pereira, Hélder; Santos, Mário; Pimenta, JoanaHeart failure (HF) with preserved ejection fraction (HFpEF) affects more than 50% of HF patients worldwide, and more than 70% of HF patients aged over 65. This is a complex syndrome with a clinically heterogeneous presentation and a multifactorial pathophysiology, both of which make its diagnosis and treatment challenging. A Portuguese HF expert panel convened to address HFpEF pathophysiology and therapy, as well as appropriate management within the Portuguese context. This initiative resulted in two position papers that examine the most recently published literature in the field. The present Part I includes a review of the HFpEF literature covering pathophysiology, clinical presentation, diagnosis and treatment, including pharmacological and non-pharmacological strategies. Part II, the second paper, addresses the development of a holistic and integrated HFPEF clinical care system within the Portuguese context that is capable of reducing morbidity and mortality and improving patients’ functional capacity and quality of life.
- Portuguese Heart Failure Prevalence Observational Study (PORTHOS) rationale and design – a population-based studyPublication . Baptista, Rui; Silva Cardoso, José; Canhão, Helena; Maria Rodrigues, Ana; Kislaya, Irina; Franco, Fátima; Bernardo, Filipa; Pimenta, Joana; Mendes, Lígia; Gonçalves, Sara; Teresa Timóteo, Ana; Andrade, Aurora; Moura, Brenda; Fonseca, Cândida; Aguiar, Carlos; Brito, Dulce; Ferreira, Jorge; Filipe Azevedo, Luís; Peres, Marisa; Santos, Paulo; Moraes Sarmento, Pedro; Cernadas, Rui; Santos, Mário; Fontes-Carvalho, Ricardo; Campos Fernandes, Adalberto; Martinho, Hugo; González-Juanatey, José Ramon; Filipe Pereira, Luís; Gil, Victor; Raquel Marques, Cláudia; Almeida, Mário; Pardal, Marisa; Barbosa, Veneranda; Gavina, CristinaIntroduction and objectives: Current epidemiological data on heart failure (HF) in Portugal derives from studies conducted two decades ago. The main aim of this study is to determine HF prevalence in the Portuguese population. Using current standards, this manuscript aims to describe the methodology and research protocol applied. Methods: The Portuguese Heart Failure Prevalence Observational Study (PORTHOS) is a large, three-stage, population-based, nationwide, cross-sectional study. Community-dwelling citizens aged 50 years and older will be randomly selected via stratified multistage sampling. Eligible participants will be invited to attend a screening visit at a mobile clinic for HF symptom assessment, anthropomorphic assessment, N-terminal pro-B-type natriuretic peptide (NT-proBNP) testing, one-lead electrocardiogram (ECG) and a sociodemographic and health-related quality of life questionnaire (EQ-5D). All subjects with NT-proBNP ≥125 pg/mL or with a prior history of HF will undergo a diagnostic confirmatory assessment at the mobile clinic composed of a 12-lead ECG, comprehensive echocardiography, HF questionnaire (KCCQ) and blood sampling. To validate the screening procedure, a control group will undergo the same diagnostic assessment. Echocardiography results will be centrally validated, and HF diagnosis will be established according to the European Society of Cardiology HF guidelines. A random subsample of patients with an equivocal HF with preserved ejection fraction diagnosis based on the application of the Heart Failure Association preserved ejection fraction diagnostic algorithm will be invited to undergo an exercise echocardiography. Conclusions: Through the application of current standards, appropriate methodologies, and a strong research protocol, the PORTHOS study will determine the prevalence of HF in mainland Portugal and enable a comprehensive characterization of HF patients, leading to a better understanding of their clinical profile and health-related quality of life.